1.
Preprint
in English
| medRxiv
| ID: ppmedrxiv-21255282
ABSTRACT
A large-scale SARS-CoV-2 serosurvey of New Zealand blood donors (n=9806) was conducted at the end of 2020. Seroprevalence, after adjusting for test sensitivity and specificity, was very low (0.1%). This finding is consistent with limited community transmission and provides robust evidence to support New Zealand s successful elimination strategy for COVID-19.